---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-054807"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2023-05-02T23:59:59+00:00"
generated_at: "2026-06-16T03:42:29.844753+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kiniksa raises ARCALYST FY2023 guidance; Q1 revenue $48.3M, net loss narrows

## Summary
- ARCALYST Q1 net product revenue $42.7M; FY2023 guidance raised to $200-215M (~69% YoY growth at midpoint).
- Net loss improved to $12.3M from $25.2M YoY; total revenue $48.3M vs $32.2M.
- Cash & short-term investments $187.5M, no debt; cash runway now expected into at least 2026.
- Final cohort of KPL-404 Phase 2 RA trial enrolling; data expected 1H 2024.
- Over 1,000 prescribers written ARCALYST scripts since launch; payer approval rate >90%.

## SEC filing metadata
- accession: 0001104659-23-054807
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2023-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465923054807/0001104659-23-054807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465923054807/tm2314130d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-054807
- JSON: https://secwatch.observer/filing/0001104659-23-054807.json
- Plain text: https://secwatch.observer/filing/0001104659-23-054807.txt

## Key facts
- Earnings Releases
  Kiniksa Pharmaceuticals International, plc reported first quarter 2023 results: revenue $48.3 million, net income $12.3 million. Guidance raised.
  - Period: first quarter 2023
  - Revenue: $48.3 million
  - Net income: $12.3 million
  - Guidance: raised
  - Result: reported results
  source text: diseases where the granulocyte macrophage colony stimulating factor (GM-CSF) mechanism has been implicated. Financial Results · Total revenue for the first quarter of 2023 was $48.3 million, compared to $32.2 million for the first quarter of 2022. - Total revenue for the first quarter of 2023 included $42.7 million in ARCALYST net product revenue and $5.7 million in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730430/000110465923054807/0001104659-23-054807-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.